uniQure Gets Its Groove On: An Interview With CEO Jörn Aldag
UniQure made history in 2012 for winning approval in the EU for the first gene therapy accepted by regulators in a major market. CEO Jörn Aldag shares his views on uniQure's ambitious expansion plans.
You may also be interested in...
As gene therapy moves closer toward becoming an established therapeutic mode, developers have focused mainly on ophthalmology and monogenic rare diseases, but improvements in vector technology are pointing the field toward targets in the central nervous system. The latest entrant is Voyager Therapeutics Inc., which launched in February with a $45 million Series A commitment from Third Rock Ventures and a lead program in Parkinson's disease.
uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy
uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.
Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.